Allarity Therapeutics FY2025 net loss $11.2M, cash $14.7M, stenoparib Fast Track

Allarity Therapeutics, Inc.

Net loss improved to $11.2M ($0.78/shr) from $25.1M ($15.65/shr) in 2024; first revenue of $320k.
Year-end cash $14.7M; extended runway with $20M non-convertible debt financing closed March 2026.
Stenoparib received FDA Fast Track for advanced ovarian cancer; new Phase 2 protocol implemented.
VA-funded Phase 2 combo trial (stenoparib+temozolomide) in SCLC opened at 11 VA sites; first patients dosed early 2026.
Jeff Ervin appointed CFO in July 2025 as part of leadership strengthening; DRP platform licensing initiated.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.